TheMicrogliaIndex

Apolipoprotein E (APOE) is the single strongest genetic risk factor for late-onset Alzheimer’s disease, and its function is deeply intertwined with microglial states. While APOE is predominantly produced by astrocytes in the healthy brain, reactive microglia dramatically upregulate APOE expression as they transition into Disease-Associated Microglia (DAM) states. In the context of Alzheimer's, APOE acts as a critical binding partner bridging amyloid plaques and microglial receptors—most notably TREM2. When microglia detect tissue damage, the massive upregulation of APOE serves as an immunometabolic bottleneck that shuts down homeostatic genes (like TGFBR1 and P2RY12) and pushes the cell toward active phagocytosis and containment of amyloid. The APOE4 isoform—which structurally differs to APOE3 and APOE2—causes a toxic gain-of-function and loss-of-clearance. Microglia expressing APOE4 exhibit impaired lipid metabolism, stunted phagocytosis, and hyper-inflammatory responses. This disrupted axis causes microglia to fail at forming protective barriers around plaques, ultimately exacerbating tau spread and directly mediating neurodegeneration.

C1QA encodes a subunit of the C1q complement complex, which is produced by microglia and tags synapses for elimination during development and disease. In Alzheimer's disease and aging, excessive C1q-mediated synaptic tagging followed by microglial phagocytosis contributes to synapse loss. C1q is markedly upregulated in the aging and diseased brain. Blocking C1q has been shown to reduce synapse loss in disease models.

CD33 (Siglec-3) operates in direct opposition to TREM2, functioning as a primary inhibitory receptor on the microglial surface. As an ITIM-containing (Immunoreceptor Tyrosine-based Inhibitory Motif) sialic acid-binding receptor, its physiological role is to "brake" microglial activation to prevent runaway inflammation. In Alzheimer's pathology, however, excessive CD33 signaling puts a pathological halt on the microglial ability to clear amyloid-beta. GWAS studies identified that higher CD33 expression correlates with significantly elevated amyloid burden and cognitive decline. The signaling axis recruits the phosphatases SHP-1 and SHP-2, which aggressively shut down the pro-phagocytic SYK signaling cascade—essentially "turning off" the cell's ability to transition into a protective state. Fascinatingly, a protective genetic variant acts as a natural CD33 inhibitor: the rs3865444 minor allele heavily favors the production of a truncated CD33 isoform (D2-CD33) that lacks the sialic acid-binding domain. Individuals with this protective variant have more phagocytically active microglia, confirming CD33 as a prime target for antagonistic antibodies (like AL003) to lift the brake off the microglial immune system.

CSF1R (Colony Stimulating Factor 1 Receptor) is the absolute, non-redundant survival receptor for the entire microglial lineage. The sheer existence of microglia in the brain relies on continuous trophic signaling through this axis via its ligands, IL-34 and CSF-1. When CSF1R signaling is pharmacologically blocked (e.g., via PLX3397), microglia rapidly and uniformly undergo apoptosis, allowing researchers to essentially "delete" microglia from the brain within a matter of days. Astoundingly, upon drug withdrawal, the brain repopulates the entire microglial compartment from surviving nestin-positive progenitors, entirely resetting the myeloid landscape. Clinically, heterozygous mutations in CSF1R lead to ALSP (Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia), an aggressive neurodegenerative condition caused by primary microglial failure. In Alzheimer's and MS, CSF1R is often targeted by pharmaceutical inhibitors to "wipe out" neurotoxic, hyper-inflammatory microglial populations, with the hypothesis that forcing a repopulation might restore a younger, more homeostatic immune environment.

LRRK2 is a multidomain kinase with roles in vesicular trafficking, autophagy, and inflammatory signaling. It is expressed in microglia and macrophages, and gain-of-function mutations (most commonly G2019S) are the most common genetic cause of Parkinson's disease. In microglia, LRRK2 regulates lysosomal function, cytokine secretion, and responses to pathogen-associated molecular patterns. LRRK2 inhibitors are in clinical trials for Parkinson's disease.

NLRP3 is an innate immune sensor that forms the NLRP3 inflammasome complex, leading to caspase-1 activation and processing of pro-IL-1β and pro-IL-18. In microglia, NLRP3 is activated by diverse damage signals including amyloid-beta fibrils, tau aggregates, and alpha-synuclein. NLRP3 inflammasome activation in microglia is implicated in neuroinflammation driving neurodegeneration. NLRP3 inhibitors are in clinical development for multiple inflammatory diseases.

Phospholipase C Gamma 2 (PLCG2) is a critical signaling enzyme uniquely enriched in microglia within the central nervous system. It functions as the direct downstream effector for TREM2 and other ITAM-containing receptors, acting as the key transducer that converts membrane receptor activation into intracellular calcium mobilization. Upon TREM2-TYROBP activation, SYK phosphorylates PLCG2, which then cleaves PIP2 into IP3 and DAG. This immediately triggers the release of calcium from the endoplasmic reticulum, an event strictly required for driving microglial phagocytosis, chemotaxis, and the transcriptional shift into the Disease-Associated Microglia (DAM) state. A rare coding variant in PLCG2 (P522R) was discovered to uniquely protect against Alzheimer's disease. This hypermorphic (gain-of-function) mutation slightly enhances the enzyme's baseline activity, allowing microglia to respond more robustly to pathological insults without becoming hyper-inflammatory. Conversely, loss-of-function variants lock microglia in a homeostatic or stalled state, entirely preventing their ability to corral amyloid plaques, cementing PLCG2 as a high-value target for pharmacological agonism to enhance neuroprotective clearance.

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is arguably the most heavily investigated microglial target in neurodegenerative disease. It operates as a critical lipid and damage-sensing receptor that orchestrates the microglial response to neurodegenerative pathologies, particularly amyloid-beta plaques and apoptotic neurons. Upon ligand binding—frequently to APOE, lipids, or polyanionic molecules—TREM2 associates with the ITAM-containing adaptor protein TYROBP (Dap12). This initiates a potent intracellular signaling cascade through SYK and PI3K pathways. This cascade is absolutely essential for driving microglia out of their homeostatic state and into the Disease-Associated Microglia (DAM) phenotype. In Alzheimer's disease, functional TREM2 signaling is required for microglia to physically barrier amyloid plaques, compacting them and preventing neurotoxic halo formation. Heterozygous loss-of-function variants (most notably R47H) severely impair this lipid-sensing and compaction ability, leading to diffuse, highly toxic plaques and an inflamed microenvironment, conferring a 2-4x increased risk for late-onset AD. Conversely, complete bi-allelic loss of TREM2 or TYROBP results in Nasu-Hakola disease, driving extreme early-onset dementia and bone cysts due to complete failure of myeloid cell clearance functionality. Therapeutics currently aim to use agonistic antibodies to artificially force-start the protective DAM state early in disease progression.